Results 131 to 140 of about 203,196 (295)
Cytometry Part B: Clinical Cytometry, EarlyView.Abstract Basophils are effector cells in type I hypersensitivity reactions. Upon cross‐linking of surface‐bound (allergen‐specific) IgE, basophils release a variety of mediators. Determining the activation of basophils ex vivo with anti‐IgE (a basophil activation test or BAT) can be achieved using flow cytometry.
T. C. Pelgrim +7 more
wiley +1 more source
Cytometry Part B: Clinical Cytometry, EarlyView.Abstract Systemic mastocytosis (SM) is a clonal mast cell (MC) disorder characterized by aberrant immunophenotypes, including expression of CD25, CD2, and occasionally CD30. CD123, the α‐subunit of the interleukin‐3 receptor, is a therapeutic target in hematologic malignancies and has been reported to be expressed on neoplastic MCs by ...
Ryan C. Shean +2 more
wiley +1 more source
Leukemia and risk of stroke: a Mendelian randomization analysis
BMC NeurologyBackground Observational studies suggest an association between leukemia and stroke, but causality remains unclear. Certain leukemia types may increase stroke risk, but variations exist in stroke and mortality rates across leukemia subtypes.
Xiaoyao Yi +4 more
doaj +1 more source
Eccrine poromatosis following chemotherapy and radiation therapy [PDF]
, 2019 Eccrine poroma presents as a single, symptomless erythematous papule in areas with a high density of eccrine sweat glands. Although rare, eccrine poromas can present as multiple lesions, otherwise known as eccrine poromatosis.
Chiu, Melvin, Kim, Gene, Nguyen, Khoa
core
Cytometry Part B: Clinical Cytometry, EarlyView.Abstract Minimal/measurable residual disease detection is routinely performed as part of post‐diagnostic treatment plans for many types of cancer, for which multiparameter flow cytometry is one possible modality frequently used. We propose a machine learning approach for binary prediction of minimal residual disease status with flow cytometry data. Our
Wikum Dinalankara +5 more
wiley +1 more source
Drug Design, Development and Therapy, 2016 Dilek Keskin, Sevil Sadri, Ahmet Emre Eskazan Department of Internal Medicine, Division of Hematology, Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey Abstract: Dasatinib is one of the second-generation tyrosine kinase inhibitors
Keskin D, Sadri S, Eskazan AE
doaj
Cytometry Part B: Clinical Cytometry, EarlyView.Abstract The objective of this 12‐color/13‐antibody single‐tube panel is to assist in the diagnosis of T/NK‐cell leukemias and lymphomas. In the clinical setting, the absence of a standardized T/NK‐cell panel limits inter‐laboratory data comparability, contributes to diagnostic variability, and results in redundant efforts across laboratories to design
Nicole So +5 more
wiley +1 more source
RORγt‐APCs: The New Masters of Oral Tolerance
Barrier Immunity, EarlyView.ABSTRACT Oral tolerance is defined by the hypo‐responsiveness of our body to fed antigens, and its failure can lead to immune‐mediated diseases, such as allergy, chronic inflammation and autoimmune diseases. Decades of research have demonstrated that antigen‐presenting cells (APCs) promote oral tolerance by inducing regulatory T cells (Tregs) and/or ...
Thierry Gauthier, WanJun Chen
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo +10 more
wiley +1 more source